Multicenter Evaluation of Colistin Broth Disk Elution and Colistin Agar Test: a Report from the Clinical and Laboratory Standards Institute
- 1 November 2019
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (11)
Abstract
Susceptibility testing of the polymyxins (colistin and polymyxin B) is challenging for clinical laboratories. The Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Subcommittee evaluated two methods to enable accurate testing of these agents. These methods were a colistin broth disk elution (CBDE) and a colistin agar test (CAT), the latter of which was evaluated using two inoculum volumes, 1 μL (CAT-1) and 10 μL (CAT-10). The methods were evaluated using a collection of 270 isolates of Enterobacterales, 122 Pseudomonas aeruginosa and 106 Acinetobacter spp. Overall, 94.4% of CBDE results were in essential agreement and 97.9% in categorical agreement (CA) with reference broth microdilution MICs. Nine very major errors (VME, 3.2%) were observed and 3 major errors (ME, 0.9%). By the CBDE, 98.6% CA was observed for Enterobacterales (2.5% VME, 0% ME), 99.3% CA for P. aeruginosa (0% VME, 0.7% ME) and 93.1% CA for Acinetobacter spp. (5.6% VME, 3.3% ME). Overall, CA was 94.9% with 6.8% VME by CAT-1 and improved to 98.3% with 3.9% VME by CAT-10. No ME were observed by either CAT-1 or CAT-10. By the CAT-1/CAT-10, 99.4%/99.7% CA was observed for Enterobacterales (1%/0.5% VME), 98.7%/100% CA for P. aeruginosa (8.3%/0% VME) and 88.5%/92.3% CA for Acinetobacter spp. (21.4%/14.3% VME). Based on these data, the CLSI AST Subcommittee endorsed the CBDE and CAT-10 methods for colistin testing of the Enterobacterales and P. aeruginosa.Keywords
This publication has 15 references indexed in Scilit:
- Two-Site Evaluation of the Colistin Broth Disk Elution Test To Determine Colistin In Vitro Activity against Gram-Negative BacilliJournal of Clinical Microbiology, 2019
- Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infectionInternational Journal of Antimicrobial Agents, 2019
- International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- Antimicrobial susceptibility testing of colistin – evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp.Clinical Microbiology and Infection, 2018
- Evaluation of colistin stability in agar and comparison of four methods for MIC testing of colistinEuropean Journal of Clinical Microbiology & Infectious Diseases, 2017
- Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysisInternational Journal of Antimicrobial Agents, 2017
- Susceptibility Testing of the Polymyxins: Where Are We Now?Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Colistin Heteroresistance in Enterobacter cloacae Is Associated with Cross-Resistance to the Host Antimicrobial LysozymeAntimicrobial Agents and Chemotherapy, 2014
- Irreproducible and Uninterpretable Polymyxin B MICs for Enterobacter cloacae and Enterobacter aerogenesJournal of Clinical Microbiology, 2013
- Colistin MIC Variability by Method for Contemporary Clinical Isolates of Multidrug-Resistant Gram-Negative BacilliJournal of Clinical Microbiology, 2013